Menu
 
Research menu
Jump to menu

Publications:  Dr Sarah Martin

Shailes H, Bridge G, Foxler D, Sharp TV, Silver A, Martin SA (2017). Targeting APC loss using synthetic lethality in Colorectal Cancer. MOLECULAR CANCER THERAPEUTICS. vol. 16,
Guillotin D, Austin P, Begum R, Freitas MO, Merve A, Brend T, Short S, Marino S et al.(2017). Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA Mismatch Repair Deficient Cells. Clin Cancer Res vol. 23, (11) 2880-2890.
10.1158/1078-0432.CCR-16-1216
https://qmro.qmul.ac.uk/xmlui/handle/123456789/19059
Locke M, Ghazaly E, Freitas MO, Mitsinga M, Lattanzio L, Lo Nigro C, Nagano A, Wang J et al.(2016). Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1. Cell Reports vol. 16, (6) 1604-1613.
10.1016/j.celrep.2016.06.097
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15049
Szlosarek PW, Locke M, Ghazaly E, Lattanzio L, Lo Nigro C, Martin SA (2016). Inhibition of the polyamine synthesis pathway is synthetically lethal with loss of argininosuccinate synthase 1 in cancer. vol. 76,
10.1158/1538-7445.AM2016-1050
Martin SA(2016). The DNA mismatch repair pathway. DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications: Second Edition,
GROSE RP, Dawkins JBN, Wang J, maniati, heward, koniali, kocher, martin et al.(2016). Reduced expression of histone methyltransferases KMT2C and KMT2D correlates with improved outcome in pancreatic ductal adenocarcinoma. Cancer Research
10.1158/0008-5472.CAN-16-0481
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12978
Begum R, Martin SA(2016). Targeting Mismatch Repair defects: A novel strategy for personalized cancer treatment. DNA Repair vol. 38, 135-139.
10.1016/j.dnarep.2015.11.026
Begum R, Martin SA(2016). Targeting Mismatch Repair defects: A novel strategy for personalized cancer treatment. DNA Repair (Amst) vol. 38, 135-139.
10.1016/j.dnarep.2015.11.026
Tookman LA, Browne AK, Connell CM, Bridge G, Ingemarsdotter CK, Dowson S, Shibata A, Lockley M et al.(2016). RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer. Mol Cancer Res vol. 14, (1) 44-55.
10.1158/1541-7786.MCR-15-0188-T
Rashid S, Bridge G, Yao Z, Szabadkai G, Martin SA (2015). Targeting the mitochondria for the treatment of MLH1-deficient disease. CANCER RESEARCH. vol. 75,
10.1158/1538-7445.AM2015-4713
Guillotin D, Martin SA(2014). Exploiting DNA mismatch repair deficiency as a therapeutic strategy. Exp Cell Res vol. 329, (1) 110-115.
10.1016/j.yexcr.2014.07.004
Stewart GD, O'Mahony FC, Laird A, Rashid S, Martin SA, Eory L, Lubbock ALR, Nanda J et al.(2014). Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. Eur Urol vol. 66, (5) 956-963.
10.1016/j.eururo.2014.04.007
Hewish M, Fontebasso Y, Martin SA, Elliott R, Perks KL, Konde A, Bajrami I, Van Weverwijk A et al. (2014). Cancer cells deficient in DNA mismatch repair (MMR) are selectively sensitive to inhibition of the DNA dependent protein kinase (DNA-PK). CANCER RESEARCH. vol. 74,
10.1158/1538-7445.AM2014-2931
Bridge G, Rashid S, Martin SA(2014). DNA mismatch repair and oxidative DNA damage: implications for cancer biology and treatment. Cancers (Basel) vol. 6, (3) 1597-1614.
10.3390/cancers6031597
Brierley DJ, Martin SA(2013). Oxidative stress and the DNA mismatch repair pathway. Antioxid Redox Signal vol. 18, (18) 2420-2428.
10.1089/ars.2012.4994
Hewish M, Martin SA, Elliott R, Cunningham D, Lord CJ, Ashworth A(2013). Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress. Br J Cancer vol. 108, (4) 983-992.
10.1038/bjc.2013.3
Martin SA, Hewish M, Sims D, Lord CJ, Ashworth A(2011). Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res vol. 71, (5) 1836-1848.
10.1158/0008-5472.CAN-10-2836
MARTIN S(2011). Mitochondrial DNA repair. DNA Repair - On the pathways to fixing DNA damage and errors, INTECH
Martin SA, Lord CJ, Ashworth A(2010). Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res vol. 16, (21) 5107-5113.
10.1158/1078-0432.CCR-10-0821
Hewish M, Lord CJ, Martin SA, Cunningham D, Ashworth A(2010). Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol vol. 7, (4) 197-208.
10.1038/nrclinonc.2010.18
Martin SA, McCabe N, Mullarkey M, Cummins R, Burgess DJ, Nakabeppu Y, Oka S, Kay E et al.(2010). DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell vol. 17, (3) 235-248.
10.1016/j.ccr.2009.12.046
Martin SA, Hewish M, Lord CJ, Ashworth A(2010). Genomic instability and the selection of treatments for cancer. J Pathol vol. 220, (2) 281-289.
10.1002/path.2631
Martin SA, McCarthy A, Barber LJ, Burgess DJ, Parry S, Lord CJ, Ashworth A(2009). Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med vol. 1, (6-7) 323-337.
10.1002/emmm.200900040
Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim J-S, Waldman T, Lord CJ et al.(2009). Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med vol. 1, (6-7) 315-322.
10.1002/emmm.200900041
Lord CJ, Martin SA, Ashworth A(2009). RNA interference screening demystified. J Clin Pathol vol. 62, (3) 195-200.
10.1136/jcp.2008.058735
Martin SA, Ouchi T(2008). Cellular commitment to reentry into the cell cycle after stalled DNA is determined by site-specific phosphorylation of Chk1 and PTEN. Mol Cancer Ther vol. 7, (8) 2509-2516.
10.1158/1535-7163.MCT-08-0199
Martin SA, Lord CJ, Ashworth A(2008). DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev vol. 18, (1) 80-86.
10.1016/j.gde.2008.01.016
Tawara H, Fujiuchi N, Sironi J, Martin S, Aglipay J, Ouchi M, Taga M, Chen P-L et al.(2008). Loss of p53-regulatory protein IFI16 induces NBS1 leading to activation of p53-mediated checkpoint by phosphorylation of p53 SER37. Front Biosci vol. 13, 240-248.
10.2741/2674
Aglipay JA, Martin SA, Tawara H, Lee SW, Ouchi T(2006). ATM activation by ionizing radiation requires BRCA1-associated BAAT1. J Biol Chem vol. 281, (14) 9710-9718.
10.1074/jbc.M510332200
Martin SA, Ouchi T(2005). BRCA1 phosphorylation regulates caspase-3 activation in UV-induced apoptosis. Cancer Res vol. 65, (23) 10657-10662.
10.1158/0008-5472.CAN-05-2087
Martin SA, Caplice NC, Davey GC, Powell R (2003). Identification of genes expressed in the liver of the Atlantic salmon (Salmo salar). Marine Biotechnology : An Overview of Leading Field. Editors: ColliecJouault, S, 90-94.
Martin SA, Caplice NC, Davey GC, Powell R(2002). EST-based identification of genes expressed in the liver of adult Atlantic salmon (Salmo salar). Biochem Biophys Res Commun vol. 293, (1) 578-585.
10.1016/S0006-291X(02)00263-2
Davey GC, Caplice NC, Martin SA, Powell R(2001). A survey of genes in the Atlantic salmon (Salmo salar) as identified by expressed sequence tags. Gene vol. 263, (1-2) 121-130.
10.1016/S0378-1119(00)00587-4
Return to top